Applied DNA Sciences Faces Delisting Concerns

TL;DR

APDN might get delisted - big trouble ahead.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on November 13, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company's transfer of listing is also mentioned, with the date of the earliest event reported as November 12, 2024.

Why It Matters

This filing indicates potential issues with Applied DNA Sciences' continued listing on an exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• November 12, 2024 (date) — Earliest event reported
• November 13, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
• $1.00 — ties to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810

Filing Documents

• tm2428275d1_8k.htm (8-K) — 26KB
• 0001104659-24-117025.txt ( ) — 194KB
• apdn-20241112.xsd (EX-101.SCH) — 3KB
• apdn-20241112_lab.xml (EX-101.LAB) — 33KB
• apdn-20241112_pre.xml (EX-101.PRE) — 22KB
• tm2428275d1_8k_htm.xml (XML) — 3KB

01. Notice of Delisting or Failure to

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 12, 2024, Applied DNA Sciences, Inc. (the "Company") received written notice (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (collectively, the "Bid Price Rule"). Based on the closing bid price of the Company's common stock, par value $0.001 per share ("Common Stock") for the thirty-one (31) consecutive business days from September 27, 2024 to November 11, 2024, the Company no longer meets the requirements of the Bid Price Rule. The Notification Letter does not impact the Company's listing on The Nasdaq Capital Market at this time. The Notification Letter states that the Company has 180 calendar days, or until May 12, 2025, to regain compliance with the Bid Price Rule. To regain compliance, the bid price of the Company's Common Stock must have a closing bid price of at least $1.00 per share for a minimum of ten (10) consecutive business days, with a longer period potentially required by the staff of Nasdaq (the "Staff"). If the Company does not regain compliance with the Bid Price Rule by May 12, 2025, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 12, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR